News
- Author:
- Laura Nikolaides
Publish date: January 10, 2019
Adiposity changes during the peripubertal period may have more of an impact on ovarian cancer risk than adiposity changes during adulthood.
News
- Author:
- Laura Nikolaides
Publish date: December 21, 2018
This is the first approved therapy for BPDCN, an aggressive and rare disease of the bone marrow and blood that can affect multiple organs, and can ...
News
- Author:
- Laura Nikolaides
Publish date: December 21, 2018
The FDA also approved a companion diagnostic, the BRACAnalysis CDx test, to identify patients with gBRCAm advanced epithelial ovarian, fallopian tu...
News
- Author:
- Laura Nikolaides
Publish date: December 17, 2018
Approval is for pediatric patients who’ve had ITP for at least 6 months but had no good response to corticosteroids, immunoglobulins, or splenectom...
News
- Author:
- Laura Nikolaides
Publish date: December 7, 2018
The FDA approved checkpoint inhibitor atezolizumab for the treatment of metastatic non-squamous NSCLC with no EGFR or ALK genomic tumor aberrations...
News
- Author:
- Laura Nikolaides
Publish date: December 5, 2018
The efficacy and cardiac toxicity profile between trastuzumab biosimilar candidate CT-P6 and trastuzumab, as neoadjuvant and then adjuvant therapy,...
News
- Author:
- Laura Nikolaides
Publish date: November 28, 2018
Results of the phase 3 STIC CTC trial will address the clinical utility of circulating tumor cells in choosing treatment approaches.
News
- Author:
- Laura Nikolaides
Publish date: November 27, 2018
Studies in HER2+ breast cancer to be presented at SABCS include a comparison of 6 vs. 12 months of trastuzumab, T-DM1 vs. trastuzumab following neo...
News
- Author:
- Laura Nikolaides
Publish date: November 27, 2018
Larotrectinib is approved for patients with solid tumors that have progressed following treatment and harbor a NTRK gene fusion without a resistanc...
News
- Author:
- Laura Nikolaides
Publish date: November 27, 2018
Investigators presented results of the phase 3 IMpas...
News
- Author:
- Laura Nikolaides
Publish date: November 5, 2018
The approval was based on an overall response rate of 48% in patients previously treated with one or more ALK kinase inhibitors.
News
- Author:
- Laura Nikolaides
Publish date: October 16, 2018
The Food and Drug Administration has approved talazoparib, a poly (ADP-ribose) polymerase (PARP) inhibitor,
News
- Author:
- Laura Nikolaides
Publish date: October 12, 2018
Results of KEYNOTE-048, a study of pembrolizumab for first-line treatment of recurrent or metastatic HNSCC, will be presented at ESMO 2018.
News
- Author:
- Laura Nikolaides
Publish date: October 11, 2018
The phase 3 trial compared immunotherapy in combination with a tyrosine kinase inhibitor to sunitinib montherapy as first-line therapy for advanced...
News
- Author:
- Laura Nikolaides
Publish date: October 8, 2018
The first presidential symposium at ESMO 2018 will feature four studies on advanced breast cancer, includi...
